These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1212 related items for PubMed ID: 15905467

  • 1. An apolipoprotein(a) peptide delays chylomicron remnant clearance and increases plasma remnant lipoproteins and atherosclerosis in vivo.
    Devlin CM, Lee SJ, Kuriakose G, Spencer C, Becker L, Grosskopf I, Ko C, Huang LS, Koschinsky ML, Cooper AD, Tabas I.
    Arterioscler Thromb Vasc Biol; 2005 Aug; 25(8):1704-10. PubMed ID: 15905467
    [Abstract] [Full Text] [Related]

  • 2. Plasma lipoprotein metabolism in transgenic mice overexpressing apolipoprotein E. Accelerated clearance of lipoproteins containing apolipoprotein B.
    Shimano H, Yamada N, Katsuki M, Yamamoto K, Gotoda T, Harada K, Shimada M, Yazaki Y.
    J Clin Invest; 1992 Nov; 90(5):2084-91. PubMed ID: 1430232
    [Abstract] [Full Text] [Related]

  • 3. Does pravastatin increase chylomicron remnant catabolism in postmenopausal women with type 2 diabetes mellitus?
    Ng TW, Watts GF, Stuckey BG, Ching HL, Chan DC, Uchida Y, Sakai N, Yamashita S, Martins IJ, Redgrave TG, Barrett PH.
    Clin Endocrinol (Oxf); 2005 Dec; 63(6):650-6. PubMed ID: 16343099
    [Abstract] [Full Text] [Related]

  • 4. Modulation of very low density lipoprotein production and clearance contributes to age- and gender- dependent hyperlipoproteinemia in apolipoprotein E3-Leiden transgenic mice.
    van Vlijmen BJ, van 't Hof HB, Mol MJ, van der Boom H, van der Zee A, Frants RR, Hofker MH, Havekes LM.
    J Clin Invest; 1996 Mar 01; 97(5):1184-92. PubMed ID: 8636429
    [Abstract] [Full Text] [Related]

  • 5. Opposing effects of apolipoprotein m on catabolism of apolipoprotein B-containing lipoproteins and atherosclerosis.
    Christoffersen C, Pedersen TX, Gordts PL, Roebroek AJ, Dahlbäck B, Nielsen LB.
    Circ Res; 2010 May 28; 106(10):1624-34. PubMed ID: 20360257
    [Abstract] [Full Text] [Related]

  • 6. Postprandial apolipoprotein B48-and B100-containing lipoproteins in type 2 diabetes: do statins have a specific effect on triglyceride metabolism?
    Battula SB, Fitzsimons O, Moreno S, Owens D, Collins P, Johnson A, Tomkin GH.
    Metabolism; 2000 Aug 28; 49(8):1049-54. PubMed ID: 10954025
    [Abstract] [Full Text] [Related]

  • 7. Treatment with apo B peptide vaccines inhibits atherosclerosis in human apo B-100 transgenic mice without inducing an increase in peptide-specific antibodies.
    Fredrikson GN, Björkbacka H, Söderberg I, Ljungcrantz I, Nilsson J.
    J Intern Med; 2008 Dec 28; 264(6):563-70. PubMed ID: 18783480
    [Abstract] [Full Text] [Related]

  • 8. Interrelationships between human apolipoprotein A-I and apolipoproteins B-48 and B-100 kinetics using stable isotopes.
    Welty FK, Lichtenstein AH, Barrett PH, Dolnikowski GG, Schaefer EJ.
    Arterioscler Thromb Vasc Biol; 2004 Sep 28; 24(9):1703-7. PubMed ID: 15242863
    [Abstract] [Full Text] [Related]

  • 9. Naringenin decreases progression of atherosclerosis by improving dyslipidemia in high-fat-fed low-density lipoprotein receptor-null mice.
    Mulvihill EE, Assini JM, Sutherland BG, DiMattia AS, Khami M, Koppes JB, Sawyez CG, Whitman SC, Huff MW.
    Arterioscler Thromb Vasc Biol; 2010 Apr 28; 30(4):742-8. PubMed ID: 20110573
    [Abstract] [Full Text] [Related]

  • 10. Increased binding of LDL and VLDL to apo B,E receptors of hepatic plasma membrane of rats treated with Fibernat.
    Venkatesan N, Devaraj SN, Devaraj H.
    Eur J Nutr; 2003 Oct 28; 42(5):262-71. PubMed ID: 14569407
    [Abstract] [Full Text] [Related]

  • 11. Apolipoprotein E*3-Leiden transgenic mice as a test model for hypolipidaemic drugs.
    van Vlijmen BJ, Pearce NJ, Bergö M, Staels B, Yates JW, Gribble AD, Bond BC, Hofker MH, Havekes LM, Groot PH.
    Arzneimittelforschung; 1998 Apr 28; 48(4):396-402. PubMed ID: 9608883
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Apolipoprotein B-100 kinetics and static plasma indices of triglyceride-rich lipoprotein metabolism in overweight men.
    Chan DC, Watts GF, Ng TW, Uchida Y, Sakai N, Yamashita S, Barrett PH.
    Clin Biochem; 2005 Sep 28; 38(9):806-12. PubMed ID: 15992790
    [Abstract] [Full Text] [Related]

  • 17. Acute elevation of plasma PLTP activity strongly increases pre-existing atherosclerosis.
    Moerland M, Samyn H, van Gent T, van Haperen R, Dallinga-Thie G, Grosveld F, van Tol A, de Crom R.
    Arterioscler Thromb Vasc Biol; 2008 Jul 28; 28(7):1277-82. PubMed ID: 18421000
    [Abstract] [Full Text] [Related]

  • 18. Amino terminal 38.9% of apolipoprotein B-100 is sufficient to support cholesterol-rich lipoprotein production and atherosclerosis.
    Chen Z, Fitzgerald RL, Saffitz JE, Semenkovich CF, Schonfeld G.
    Arterioscler Thromb Vasc Biol; 2003 Apr 01; 23(4):668-74. PubMed ID: 12615667
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE*3-Leiden mice.
    Westerterp M, van der Hoogt CC, de Haan W, Offerman EH, Dallinga-Thie GM, Jukema JW, Havekes LM, Rensen PC.
    Arterioscler Thromb Vasc Biol; 2006 Nov 01; 26(11):2552-9. PubMed ID: 16946130
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 61.